Compare MYSZ & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYSZ | XRTX |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 4.4M |
| IPO Year | N/A | N/A |
| Metric | MYSZ | XRTX |
|---|---|---|
| Price | $0.85 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 276.4K | 32.8K |
| Earning Date | 11-14-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,512,000.00 | N/A |
| Revenue This Year | $18.06 | N/A |
| Revenue Next Year | $36.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $0.51 |
| 52 Week High | $3.04 | $1.41 |
| Indicator | MYSZ | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 45.75 |
| Support Level | $0.82 | $0.55 |
| Resistance Level | $0.88 | $0.60 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 17.81 | 30.62 |
My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.